

**Institute of Fundamental Technological Research Polish Academy of Sciences  
Pawinskiego 5B, WARSAW**

*The principle aim of the ninth HNN2.0 on-site training is to give a highly interactive and complete overview on international cooperation and legal and financial issues in SC1. The first day of the training, you will have the opportunity to know more in-depth about international cooperation and get best practices from real projects within different initiatives. For the second day, it is foreseen a wide insight into the use of unit costs with an open discussion and to delve into health-related issues on FTO and IPR.*

**DAY 1 – 15<sup>TH</sup> May**

9.00 – 9.30	<b>Registration and welcome coffee</b>
9:30-9:45	Welcome and introduction to the training by HNN2.0 representatives
<b>INTERNATIONAL COOPERATION</b>	
9:45-11:45	<u>INCO in IMI-2</u> <ul style="list-style-type: none"> <li>- The specific case of IMI-2 JU – <i>Hugh Laverty, Head of Scientific Operations, IMI</i></li> <li>- The view from a coordinator – <i>Ferran Sanz, Director, Research Programme on Biomedical Informatics (GRIB), Spain - Coordinator of eTRANSAFE project</i></li> </ul>
<i>Coffee Break (11:45-12:15)</i>	
12:15-12:45	<u>Collaboration with Third Countries</u> <ul style="list-style-type: none"> <li>- EU/USA collaboration – <i>Martina De Sole, Head of International Cooperation, APRE</i></li> </ul>
Questions & Answers	
<i>Lunch Break (13:00-14:00)</i>	
14:00-14:30	<u>Collaboration with Third Countries</u> <ul style="list-style-type: none"> <li>- EU/Canada collaboration – <i>Martina De Sole, Head of International Cooperation, APRE</i></li> </ul>
Questions & Answers	
14:45-16:30	<u>EDCTP</u> <ul style="list-style-type: none"> <li>- The specific case of EDCTP – <i>Abdoulie Barry, Director of Finance and Administration EDCTP</i></li> <li>- The view from a coordinator - <i>Olaf Valverde Mordt, Medical Manager, Drugs for Neglected Diseases Initiative, Switzerland - Coordinator of HAT-r-ACC project</i></li> </ul>
Questions & Answers	
17:00	<b>Final discussion and closing remarks</b>

**DAY 2 – 16<sup>TH</sup> May**

9.30 – 9.45	<b>Registration and welcome coffee</b>
<b>LEGAL &amp; FINANCIAL ISSUES in SC1</b>	
9:45-11:00	Unit costs in clinical trials: the experience from a coordinator (open discussion) <i>Clemens Lässig, University of Tübingen, Germany</i>
<i>Coffee Break (11:00-11:15)</i>	
11:15-12:15	Freedom to Operate in Horizon 2020 <i>Michele Dubbini Eurice GmbH / Project Officer European IPR Helpdesk</i>
12:15-13:15	IPR in Health projects <i>Michele Dubbini Eurice GmbH / Project Officer European IPR Helpdesk</i>
Questions & Answers	
13:30	<b>Final discussion and closing remarks</b>